No-HK n = 1,046,966 | HK n = 161,849 | P-value | ||
---|---|---|---|---|
Mean age (years) | 43 ± 18 | 60 ± 18 | < 0.0001 | |
Age categories | < 0.0001 | |||
< 65 years | 86% | 56% | ||
65–74 years | 8% | 20% | ||
≥ 75 years | 6% | 24% | ||
Sex (male) | 41% | 51% | < 0.0001 | |
CCI | 1.7 ± 1.4 | 3.5 ± 2.8 | < 0.0001a | |
Mean baseline sK (mmol/L)b | 4.07 ± 0.39 | 5.38 ± 0.48 | < 0.0001 | |
Traditional CV Risk Factors | ||||
Hypertension | 20% | 63% | < 0.0001 | |
Hyperlipidaemia | 17% | 55% | < 0.0001 | |
Diabetes | 7% | 33% | < 0.0001 | |
Smoking | 13% | 26% | < 0.0001 | |
Renal insufficiency | 0.7% | 16% | < 0.0001 | |
BMI, kg/m2, n = 662,888 | 28.4 ± 7.4 | 29.7 ± 8.1 | < 0.0001 | |
BMI categories (kg/m2) | < 0.0001 | |||
< 25 | 36% | 29% | ||
25–29.9 | 31% | 31% | ||
≥ 30 | 33% | 40% | ||
Maximum SBP (mm Hg) | 139.2 ± 71.6 | 162.8 ± 73.7 | < 0.0001 | |
EF (%) | 60.9 ± 10.2 | 58.0 ± 12.9 | < 0.0001 | |
Prior Diagnoses | ||||
ASCVD | 4% | 21% | < 0.0001 | |
CAD | 1% | 7% | < 0.0001 | |
MI | 0.6% | 4% | < 0.0001 | |
Stroke | 0.3% | 2% | < 0.0001 | |
TIA | 0.7% | 4% | < 0.0001 | |
PVD | 0.1% | 1% | < 0.0001 | |
Heart failure | 2% | 20% | < 0.0001 | |
Atrial fibrillation | 2% | 14% | < 0.0001 | |
Baseline Medications | ||||
Statin | 7% | 39% | < 0.0001 | |
Other anti-diabetic | 1% | 10% | < 0.0001 | |
Insulin | 2% | 24% | < 0.0001 | |
Metformin | 3% | 18% | < 0.0001 | |
Sulfonylurea | 1% | 11% | < 0.0001 | |
NSAID | 39% | 62% | < 0.0001 | |
ACEi | 8% | 39% | < 0.0001 | |
ARB | 3% | 16% | < 0.0001 | |
Aldosterone inhibitor | 0.6% | 6% | < 0.0001 | |
Beta-blocker | 6% | 32% | < 0.0001 | |
Diuretic | 9% | 42% | < 0.0001 | |
CCB | 4% | 22% | < 0.0001 | |
Furosemide | 3% | 24% | < 0.0001 | |
Torsemide | 0.1% | 1.2% | < 0.0001 | |
SPS | 0.04% | 0.4% | < 0.0001 | |
Patiromer | 0% | 0% | – | |
3-Year Post-Index Outcomes (n = 1,128,582) | ||||
n = 983,409 | n = 145,173 | |||
MACEc | 3.2% | 18.8% | < 0.0001 | |
Death | 2.9% | 16.7% | < 0.0001 | |
MI | 0.05% | 0.2% | < 0.0001 | |
Stroke | 0.2% | 0.9% | < 0.0001 | |
HFH | 0.2% | 2.8% | < 0.0001 | |
Multivariable Hazard Ratio (95% CI) for 3-Year MACEc | ||||
No-HK vs HK | 1.60 (1.57, 1.63), P < 0.0001 | |||
Post-Index Average Costs/Year (n = 1,208,815) | ||||
ED | < 0.0001a | |||
Cost ± SD | $207 ± 1,930 | $552 ± 7,574 | ||
Median (IQR) | 11 (0, 187) | 56 (0, 408) | ||
Inpatient | < 0.0001a | |||
Cost ± SD | $1,477 ± 21,423 | $10,956 ± 93,026 | ||
Median (IQR) | 0 (0, 740) | 0 (0, 4585) | ||
Age ≥ 60 years Post-Index Average Costs/Year (n = 290,972) | ||||
ED | < 0.0001a | |||
Cost ± SD | $222 ± 2,747 | $561 ± 7,098 | ||
Median (IQR) | 18 (0, 219) | 72 (0, 444) | ||
Inpatient | < 0.0001a | |||
Cost ± SD | $3,765 ± 35,137 | $13,844 ± 109,257 | ||
Median (IQR) | 0 (0, 2307) | 1,277 (0, 6678) |